ERBB2 and neoplasm: Except for ER/PR−/HER2+ tumor subtypes, ER/PR/HER2− tumors, also called triple-negative breast cancer (TNBC), show aggressive behavior and poor outcome, with the highest mortality rate and recurrence, and are least likely to respond to hormone therapy.